Jiangxi Fushine Pharmaceutical Co., Ltd.

Pharmaceutical Manufacturing

The company is a leading global production hub and major supplier of β-lactamase inhibitors, and one of the few enterprises in China with an integrated value chain for carbapenem and penem series products - from starting materials to active pharmaceutical ingredients (APIs).
- Tazobactam
- Piperacillin
- Sultamicillin
- Sulbactam
- 4-AA
- A9
Learn more
New Energy

The company is actively developing a one-stop supply platform for lithium battery electrolyte materials, with its shipments of vinylene carbonate (VC) ranking among the industry leaders.
Learn more
Synthetic Biology & Biotechnology

The company is the first enterprise in Asia to achieve industrial-scale production of filamentous fungal protein, and its FuNext mycoprotein has obtained US SELF-GRAS certification.
Learn more

FUSHINE

Advancing Health through Science

Delivering Responsibility through Action

We are committed to advancing sustainability governance and shaping a comprehensive sustainability strategy.

Learn more

Innovating with Commitment,
Leading the Whole Value Chain

SINCE

2002

The company will continue to align with its long-term development strategy, focusing on the three core business segments with precision and excellence. We are committed to being a globally recognized leader in pharmaceutical manufacturing, a leading global supplier of new energy materials, and a benchmark enterprise in microbial protein.

Stock Code

300497

Listed on the Shenzhen Stock Exchange's ChiNext board in December 2015

74.66

Million Yuan R&D Investment in 2024
1700+

Number of Employees
8

Production Bases